Methods to regulate polarization and enhance function of cells

• US 10,022,457 B2
• Filed: 06/17/2015
• Issued: 07/17/2018
• Est. Priority Date: 08/05/2005
• Status: Active Grant

• Current Assignee: Gholam A. Peyman
• Original Assignee: Gholam A. Peyman
• Inventors: Peyman, Gholam A.
• Primary Examiner(s): Popa, Ileana
• Application Number:
  US14/742,323
• Publication Number:
  US 20150283265A1
• Time in Patent Office: 1,126 Days
• Field of Search: None
• CPC Class Codes: A61B 2017/00345 Micromachines, nanomachines, microsystems
• CPC Class Codes: A61B 5/1114 Tracking parts of the body
• CPC Class Codes: A61B 5/24 Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• CPC Class Codes: A61B 5/6867 specially adapted to be attached or implanted in a specific body part A61B5/6847 takes precedence
• CPC Class Codes: A61F 9/0079 using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
• CPC Class Codes: A61F 9/008 using laser
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 41/0042 Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/6923 the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• CPC Class Codes: A61K 47/6929 the form being a nanoparticle, e.g. an immuno-nanoparticle
• CPC Class Codes: A61K 48/0041 the non-active part being polymeric
• CPC Class Codes: A61K 49/0067 quantum dots, fluorescent nanocrystals
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61N 2005/063 comprising light transmitting means, e.g. optical fibres
• CPC Class Codes: A61N 2005/0651 Diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 2005/0661 ultraviolet
• CPC Class Codes: A61N 2005/0662 : Visible light
• CPC Class Codes: A61N 5/0601 : Apparatus for use inside the body
• CPC Class Codes: A61N 5/0613 : Apparatus adapted for a specific treatment
• CPC Class Codes: A61N 5/062 : Photodynamic therapy, i.e. excitation of an agent
• CPC Class Codes: A61N 5/0622 : Optical stimulation for exciting neural tissue
• CPC Class Codes: A61N 5/067 : using laser light
• CPC Class Codes: B82Y 30/00 : Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Methods and compositions to controllably regulate cells at a target site. A quantum dot-targeting agent complex is administered to a patient in need of therapy, and the complex is stimulated using an implanted fiber optic system. In embodiments, the system includes an electrical sensor that detects and monitors electrical activity of the stimulated controllably regulated cells, and relays this information to a controller that can regulate further stimulation.

Claims

1. A method for at least one of editing or regulating a gene in a target excitable cell, the method comprising

administering to a patient in need thereof a plurality of nanoparticles coated with a biocompatible molecule for cell uptake, the nanoparticles conjugated with at least one opsin family gene, a second unmutated gene other than the opsin family gene which ameliorates a genetic or acquired degenerative disease or condition, an antibody that targets the nanoparticles to the target excitable cell, and a CRISPR/cas9 complex to form a complex of coated nanoparticle-gene-CRISPR/cas9;

delivering the nanoparticle-gene-CRISPR/cas9 complex to the target cell using the nanoparticle of the complex as a carrier without using a viral vector, and stimulating the complex and the target excitable cell with one or more energy sources under conditions sufficient to introduce the at least one opsin-family gene, the second gene, and the CRISPR/cas9 complex into the target excitable cell;

using the CRISPR/cas9 complex to excise from the DNA of the target excitable cell a DNA segment bearing a mutation inducing the genetic or acquired degenerative disorder or condition; and

replacing the excised mutated DNA segment with the second unmutated gene to treat the patient;

wherein stimulating the complex and the target excitable cell with one or more energy sources includes stimulating the nanoparticle of the complex and the target excitable cell with light.

2. The method of claim 1, wherein the DNA of the target excitable cell is selected from the group consisting of nuclear DNA and mitochondrial DNA.

3. The method of claim 1 where the excitable cell is selected from the group consisting of a retinal cell, a central nervous system neuronal cell, a central nervous system glial cell, a spinal cord cell, a peripheral nerve cell, a cardiac cell, and combinations thereof.

4. The method of claim 1 where the complex is administered systemically or locally.

5. The method of claim 1 where the complex is administered to a site selected from the group consisting of intraocular, intravitreal, intrathecal, brain ventricle, proximate a central nervous system neuron, proximate a peripheral nerve, or intracardiac.

6. The method of claim 1, where the nanoparticles include piezoelectric nanoparticles and the stimulating step further includes remotely controlling the piezoelectric nanoparticles to wirelessly stimulate the piezoelectric nanoparticles and produce an electrical current resulting in wirelessly altering the membrane or action potential of the target excitable cell in contact with the piezoelectric nanoparticles.

7. The method of claim 6, where wirelessly altering the membrane or action potential results in a response selected from the group consisting of hyperpolarization, hypopolarization, and depolarization.

8. The method of claim 6, where remotely controlling the piezoelectric nanoparticles is via an ultrasound probe.

9. The method of claim 6 where the piezoelectric nanoparticles are administered by a route selected from the group consisting of injecting submucosally, spraying the nasal mucosa, and combinations thereof, where the piezoelectric nanoparticles travel through olfactory nerves to the brain that is stimulated with an externally applied ultrasound over the nose by the patient as needed.

10. The method of claim 1 where the nanoparticles include piezoelectric nanoparticles and the stimulating step further includes remotely controlling the piezoelectric nanoparticles to wirelessly stimulate the piezoelectric nanoparticles and control a diode laser surgically implanted in the patient to produce laser light for stimulating the target excitable cell with the at least one opsin-family gene, and the piezoelectric nanoparticles act as an “

on”

/“

off”

switch of a battery supplying electricity to the diode laser.

11. The method of claim 10 where stimulation is controlled by a programmable processor of an extra-corporal ultrasonic probe wirelessly controlled by the diode laser.

12. The method of claim 10 where the diode laser is surgically implanted at a site selected from the group consisting of external to the skull, internal to the skull, adjacent to an organ, adjacent to sympathetic ganglion cells, adjacent to parasympathetic ganglion cells, adjacent to the brain, adjacent to the heart, adjacent to an eye, adjacent to the spinal cord, adjacent to peripheral nerves, and combinations thereof.

13. The method of claim 6 where the piezoelectric nanoparticles are rendered biocompatible by coating with a compound selected from the group consisting of zirconate titanate, perovskite-based, oxides, barium titanate, polyvinylidene fluoride (PVDF), and combinations thereof.

14. The method of claim 11 where a ribbon of piezoelectric nanoparticles is attached to the battery of the diode laser that, upon ultrasound stimulation, creates a pulsating electrical current in the piezoelectric nanoparticles attached to the battery of the diode laser, thus controlling activation of the diode laser light production and initiating an “

on”

/“

off”

action potential in the membrane of excitable cells depending on the frequency and duration of the electrical pulse.

15. The method of claim 1 where the light stimulating the nanoparticle of the nanoparticle-gene-CRISPR/cas9 complex is delivered by a fiber optic.

16. The method of claim 1, wherein stimulating the complex and the target excitable cell with light further comprises stimulating both the nanoparticle of the complex and the opsin expressed by the target excitable cell with a particular wavelength of light to produce a complementary effect that results in an enhanced action potential in the target excitable cell.

17. A method for at least one of editing or regulating a gene in a target excitable cell, the method comprising administering to a patient in need thereof a plurality of nanoparticles coated with a biocompatible molecule for cell uptake, the nanoparticles conjugated with at least one opsin-family gene, a second unmutated gene other than the opsin family gene which ameliorates a genetic or acquired degenerative or condition, an antibody that targets the nanoparticles to the target excitable cell, and a CRISPR/cas9 complex to form a complex of coated nanoparticle-gene-CRISPR/cas9, the nanoparticles including piezoelectric nanoparticles;

delivering the nanoparticle-gene-CRISPR/cas9 complex to the target excitable cell using the nanoparticle of the complex as a carrier without using a viral vector and stimulating the complex and the target excitable cell with an energy source under conditions sufficient to introduce the at least one opsin-family gene, the second unmutated gene, and the CRISPR/cas9 complex into the target excitable cell; and

using the CRISPR/cas9 complex to excise a DNA segment bearing a mutation inducing the genetic or acquired degenerative or condition from the target excitable cell; and

replacing the excised mutated DNA segment with the second unmutated gene to treat the patient;

wherein stimulating the complex and the target excitable cell further comprises remotely controlling the piezoelectric nanoparticles with an ultrasound probe to wirelessly stimulate the piezoelectric nanoparticles and control a diode laser surgically implanted in the patient to produce laser light for stimulating the target excitable cell expressing the at least one opsin-family gene, the piezoelectric nanoparticles acting as an “

on”

/“

off”

switch of a battery supplying electricity to the diode laser, and wherein a ribbon of piezoelectric nanoparticles are attached to the battery of the diode laser that, upon ultrasound stimulation, creates a pulsating electrical current in the piezoelectric nanoparticles attached to the battery of the diode laser, thus controlling activation of the diode laser light production.